 MonjuviU.S. net product sales of 12.9 million US 15.5 million Tremfya royalties of 11.6 million Reaffirming group revenue guidance of 150 to 200 million Conference call and webcast in English tomorrow, May 6, 2021 at 2:00pm CEST 1:00pm BST8:00am EDT PLANEGGMUNICH, GERMANY ACCESSWIRE May 5, 2021 MorphoSys AG FSE:MOR; NASDAQ:MOR reports financial results for the first quarter of 2021. For 2021, our focus is on three key areas: executing on the Monjuvi launch; rapidly advancing the tafasitamab backbone strategy through additional clinical studies; and expanding our pipeline, said Jean-Paul Kress, M.D. 